Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
about
Towards Rational Design of a Toxoid Vaccine against the Heat-Stable Toxin of Escherichia coliPyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea.Epithelial cells and their neighbors. II. New perspectives on efferent signaling between brain, neuroendocrine cells, and gut epithelial cells.Multiple lineage specific expansions within the guanylyl cyclase gene familyAfferent activity to necklace glomeruli is dependent on external stimuli.Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin.The uroguanylin system and human disease.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromePlecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC miceBacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.Uroguanylin: how the gut got another satiety hormoneA uroguanylin-GUCY2C endocrine axis regulates feeding in mice.Olfactory receptors: G protein-coupled receptors and beyond.The rat kidney contains high levels of prouroguanylin (the uroguanylin precursor) but does not express GC-C (the enteric uroguanylin receptor).Contribution of the receptor guanylyl cyclase GC-D to chemosensory function in the olfactory epithelium.Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.Membrane guanylyl cyclase receptors: an updateThe receptor guanylyl cyclase type D (GC-D) ligand uroguanylin promotes the acquisition of food preferences in miceCirculating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules.Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide.Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer.The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomersFunctional analysis of the guanylyl cyclase type D signaling system in the olfactory epithelium.Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.Emerging drugs for chronic constipation.Type 2 cGMP-dependent protein kinase regulates homeostasis by blocking c-Jun N-terminal kinase in the colon epithelium.Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment.The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.Guanylin peptide family: history, interactions with ANP, and new pharmacological perspectives.The multiple and enigmatic roles of guanylyl cyclase C in intestinal homeostasis.Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.Cyclic nucleotide signaling in intestinal epithelia: getting to the gut of the matter.Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.Pendrin, a novel transcriptional target of the uroguanylin system.Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.cGMP Signaling Increases Antioxidant Gene Expression by Activating Forkhead Box O3A in the Colon Epithelium.The normal increase in insulin after a meal may be required to prevent postprandial renal sodium and volume losses.Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa.Uroguanylin regulates net fluid secretion via the NHE2 isoform of the Na/H+ exchanger in an intestinal cellular model.
P2860
Q30277331-DAE3DBB0-61C5-458A-A0B0-B10022B45DDFQ30440623-4A2EBDE7-15BB-402D-A3A2-888B77DAD667Q33221503-F55B9208-B3CD-4A51-BB1D-59D94367B31CQ33237078-04B62981-DD44-4804-8BF0-A4F2CF1E457DQ33417990-012D1CB6-A659-42E6-AFBB-55F6C243E161Q33899693-8DE45659-3E67-4142-A231-F9815F26E89AQ34293073-E5A94E20-BF27-404C-99E0-F21BA0AF0421Q34345704-BA789027-A4DD-470E-BA75-18653F0A417AQ34551599-785E9F3C-EBDD-4DA0-8A7D-E4826674BF15Q35155933-FFD5024C-4231-4B3E-8BD9-F4C13A2BC8DAQ35187154-B5EF31BC-A1AF-4181-9091-49218197FC35Q35572696-B20EAF5A-160B-4823-A989-4A552EB0F823Q35684244-093BC9A5-C8EB-439C-9949-3C1617087DB1Q35760474-768A93E2-1978-438F-ACB4-ED86A9578AC7Q35971599-78ED014F-381A-4363-BA4C-21C9DCFD628EQ36254155-A94137ED-7E2D-4473-9F20-3D058496AE3FQ36525043-A9330900-FC6C-4DBF-8523-20E19C4D9012Q36854953-29BAC27F-E19B-460D-8E63-1C0541209B71Q36908897-FED0CB32-A862-400D-BB65-14E2489F1652Q36908915-76ABBDBF-784E-4431-8B49-B32BC4A433F3Q37082792-93D3EAE4-AB75-42A6-AF10-43A15042AAC4Q37312567-9C7D19E1-D7BD-4ECC-868F-DBAFA027CA4CQ37394335-923C929E-528E-4ED3-92B5-E49B4F5AFC52Q37486782-09A6734F-6B39-48D9-A464-3193F69F0668Q37570550-6F2F5F1D-CC4B-4962-BF0B-91D84E0F2BF6Q37578804-62F5F856-9093-4E37-9E11-4DEFEEC75EAFQ37783622-F8A0A70A-5004-4CEE-9524-F3394F6320C5Q37855854-BFF8A60B-0160-4D99-8D66-539DB2672FAEQ37859025-F5CF4F8B-5DC9-47DC-B11F-ECA8270E63CDQ37911512-5AE357DC-1D27-4F32-9030-0522634625B7Q38028211-B22A929C-0D27-419F-A46C-117F035824AEQ38086870-8561E5BC-BAFA-4735-89D0-81049922B750Q38101024-646EDE84-93E0-4C73-B434-0FC1A49180B6Q38167684-B954EA05-72C1-4B4E-BEA8-B56C6AC9D0EAQ38178827-19F2B6F1-FA9E-4502-B656-4E9A63FFEDB3Q38236209-B2F4F0E6-8DC7-495A-8EDF-64218595A7E4Q38725204-319B8F2B-32ED-47A2-A77E-A8FE0714914BQ38885336-EB9D13E3-C05D-46F2-BD7A-04D5DFAA54DEQ39353975-C9067DF0-815D-4303-A0F7-6E0A7F326AC7Q39426430-CF99ABD2-DC4C-492A-B453-54D15F947B2B
P2860
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@ast
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@en
type
label
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@ast
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@en
prefLabel
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@ast
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@en
P1476
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
@en
P2093
Leonard Ralph Forte
P304
P356
10.1016/J.PHARMTHERA.2004.08.007
P577
2004-11-01T00:00:00Z